You are here

sheeloopoonam@yahoo.com's blog

Congenital Rubella Syndrome

CRS is a group of birth defects that occur when a woman gets infected with rubella virus during pregnancy. The virus can harm the developing fetus and result in a range of physical and intellectual disabilities, including deafness, blindness, heart defects and intellectual disabilities.
CRS is a preventable disease and can be avoided by ensuring the girls and women are vaccinated against rubella well before they are pregnant.
Symptoms of CRS may not appear immediately after birth and may take weeks or even months to develop. The severity of CRS can vary.

MR Vaccine

Live attenuated vaccine, containing Measle and Rubella
Storage: +2 to +8 degree Celsius
Use within 4 hours of reconstitution
At the session site: Keep in the WELL of the icepack
Open vial policy: NOT applicable
Extremely sensitive to sunlight, therefore packaged in dark color glass
Vial: contains 10 doses
DOSE: 0.5 ml
ROUTE: Subcutaneous
SITE: Right upper arm

MR Vaccine

MR Campaign

It was launched in 2017. Simultaneously, the measles vaccine in the NIS (National Immunization Schedule) was replaced with MR vaccine. Hence, currently two doses of MR vaccines are given under the NIS.
1. At 9 to 12 months of age
2. At 16 to 24 months of age
It is a mass vaccination carried out as periodic events lasting 4 to 6 weeks each. Follow-up campaigns are also organized.
The purpose is to:
• Eliminate Measles, which is an extremely contagious disease with high mortality.
• Control (Reduce the incidence) of ‘Congenital Rubella Syndrome (CRS)

Td Vaccine

Td vaccine contains of tetanus toxoid and diphtheria toxoid, but the concentration of diphtheria antigen is lower than that in DPT, DT or Pentavalent etc.
• Td vaccine is sensitive to both freezing and heat.
• It is WHO prequalified
• Open vial policy is applicable to Td vaccine.
• Shake test valid for testing for any damage by accidental freezing
• Td vaccine is safe even for use in the pregnant women

Pages

Subscribe to RSS - sheeloopoonam@yahoo.com's blog